Hennion & Walsh Asset Management, Inc. - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.

Quarter-by-quarter ownership
Hennion & Walsh Asset Management, Inc. ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$2,320,059
+159573.7%
87,981
+4.1%
0.15%
+72.1%
Q2 2023$1,453
+1.0%
84,487
-2.6%
0.09%
-2.3%
Q1 2023$1,439
+111.0%
86,763
-3.1%
0.09%
+109.5%
Q4 2022$682
-99.9%
89,505
+14.2%
0.04%
-17.6%
Q3 2022$779,000
+45.9%
78,353
+33.2%
0.05%
+54.5%
Q2 2022$534,00058,8450.03%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders